Clinical outcomes. (A) Rate of OS. At 21 months, OS was 78.7% (95% CI, 65.8-94). (B) Rate of EFS. At 21 months, EFS was 78.8% (95% CI, 66-94). (C) Rate of OS at 21 months based on postinduction (week 4) MRD status: 55.6% (95% CI, 31-99.7) in MRD-positive group vs 90.9% (95% CI, 79.7-100) in the MRD-negative group. (D) Rate of EFS at 21 months based on postinduction (week 4) MRD status: 50% (95% CI, 31-99.7) in the MRD-positive group vs 90.9% (95% CI, 79.7-100) in the MRD-negative group. Censoring of data are indicated by vertical bars.